Latest News Archive

Please select Category, Year, and then Month to display items
Previous Archive
04 April 2024 | Story Leonie Bolleurs | Photo Stephen Collett
Prof Frank Zachos
Prof Frank Zachos recently delivered his inaugural lecture on the UFS Bloemfontein Campus.

Prof Frank Zachos, a scientist and Head of the Mammal Collection at the Natural History Museum (NHM) in Vienna – one of the world’s largest natural history museums – recently delivered his inaugural lecture at the University of the Free State (UFS) on the Bloemfontein Campus.

His lecture was titled: Of bat bombs and super moms – the wondrous and wondrously curious world of mammals.

Prof Zachos, an affiliated researcher at the UFS, says he chose mammals as the topic of his lecture because he is a mammalogist and curator of mammals at the Natural History Museum. Additionally, he collaborates with Prof Paul Grobler, Head of the Department of Genetics, on mammal projects.

Exposure to almost unparalleled biodiversity in SA

With a mixture of entertaining fun facts and some proper research results, he presented his lecture, providing an overview of some of the most interesting aspects of mammals. These included their different ways of reproduction: the platypuses laying eggs, the tiny marsupial offspring growing in a pouch, and placental mammals having long gestation times. Furthermore, he compared levels of biodiversity in South Africa and Europe and highlighted some particularly bizarre mammals, such as the aye-aye, naked mole-rat, the platypus, and two extinct South African ungulates from their collection in Vienna – the quagga and the blue antelope.

Prof Zachos also discussed his own research on blue antelope genetics, as well as research on other species, in the context of the detrimental impact humans have on mammals and other wildlife.

Moreover, his lecture included a reference to Project X-Ray, a story of how the US army pursued an unsuccessful plan to use bats as carriers of mini bombs in World War II.

Prof Zachos, who is specifically known for his research on the systematics, biogeography, and genetics of red deer, as well as his theoretical work on the species problem (‘what is a species?’ –  one of the most hotly debated topics in evolutionary biology), is affiliated with the UFS due to his longstanding collaboration with Prof Grobler. He says they have known each other for a long time, have published together, and that he has also served as an external reviewer for several theses coming from the Department of Genetics.

“Apart from this personal connection, what made this collaboration particularly interesting to me from a professional viewpoint, is the rich wildlife biodiversity and the research focus of Prof Grobler’s research group, which overlaps significantly with my own longstanding interests,” adds Prof Zachos.

“Working with Prof Grobler, I am involved in studies on the genetic diversity and structuring of different mammal species occurring in South Africa. The opportunity to spend time in the field for sample collection and other activities is definitely also a highlight,” remarks Prof Zachos.

Ideal combination of academic and personal growth

Regarding his connection with the UFS and its impact on shaping the future direction of his research, he states that he has a strong interest in antelopes – a group of mammals not found in Europe, but very prominent in South Africa. “Apart from that, people in the Department of Genetics have expertise in relevant areas that I personally do not have, for example bioinformatics. For me, it is the ideal combination of academic and personal growth, and I am very grateful to have this unique opportunity.”

He believes that his affiliation with the UFS and its Department of Genetics will continue to provide him with opportunities to expand his research and knowledge to different species and ecosystems.

Beyond science, he says that he has developed an interest in the country as well. “I have been reading books about South Africa, and I consider myself very privileged to have a second academic home here, which gives me the opportunity for exchange with people of different backgrounds,” he comments.

News Archive

Cardiology Unit involved in evaluation of drug for rare genetic disease
2013-01-04

Front from the left, are: Marinda Karsten (study coordinator and registered nurse),
Laumarie de Wet (clinical technologist), Charmaine Krahenbuhl (study coordinator and radiographer),
Lorinda de Meyer (administrator), Andonia Page (study coordinator and enrolled nurse);
back Dr Gideon Visagie (sub investigator), Dr Derick Aucamp (sub investigagtor),
Prof. Hennie Theron, (principal investigator) and Dr Wilhelm Herbst (sub investigator).
Photo: Supplied
09 January 2013


The Cardiology Research Unit at the University of the Free State (UFS) contributed largely to the evaluation of the drug Juxtapid (lomitapide), which was developed by the Aegerion pharmaceutical company and approved by the FDA (Federal Drug Administration). Together with countries such as die USA, Canada and Italy, the UFS’ Unit recruited and evaluated the most patients (5 of 29) for the study since 2008.  

The drug was evaluated in persons with so-called familial homozygous hypercholesterolemia (HoFH).  

Following its approval by the FDA, Juxtapid is now a new treatment option for patients suffering from HoFH. The drug operates in a unique way which brings about dramatic improvements in cholesterol counts.  

According to Prof. Hennie Theron, Associate Professor in the Department of Cardiology at the UFS and Head of the Cardiology Contract Research Unit, HoFH is a serious, rare genetic disease which affects the function of the receptor responsible for the removal of low-density lipoprotein cholesterol (LDL-C) (“bad” cholesterol) from the body. Damage to the LDL receptor function leads to extremely high levels of blood cholesterol. HoFH patients often develop premature and progressive atherosclerosis, which is a narrowing or blockage of the arteries.  

“HoFH is a genetically transmitted disease and the most severe form of hypercholesterolemia. Patients often need a coronary artery bypass or/and aortic valve replacement before the age of 20. Mortality is extremely high and death often occurs before the third decade of life. Existing conventional cholesterol-lowering medication is unsuccessful in achieving normal target cholesterol values in this group of patients.  

“The only modality for treatment is plasmapheresis (similar to dialysis in patients with renal failure). Even with this type of therapy the results are relatively unsatisfactory because it is very expensive and the plasmapheresis has to be performed on a regular basis.  

“The drug Juxtapid, as currently evaluated, has led to a dramatic reduction in cholesterol values and normal values were achieved in several people. No existing drug is nearly as effective.  

“The drug represents a breakthrough in the treatment of familial homozygous hypercholesterolemia. The fact that it has been approved by the FDA, gives further impetus to the findings,” says Prof. Theron.  

In future further evaluation will be performed in other forms of hypocholesterolemia.  

According to Prof. Theron, the findings of the study, as well as the recent successful FDA evaluation, once again confirms the fact that the UFS’ Cardiology Contract Research Unit is doing outstanding work.  

Since its inception in 1992, the Unit has already been involved in more than 60 multi-centre, international phase 2 and 3 drug studies. Several of these studies, including the abovementioned study, really affected the way in which cardiology functions.  

The UFS’ Cardiology Contract Research Unit is being recognised nationally and internationally for its high quality of work and is constantly approached for their involvement in new studies.  

We use cookies to make interactions with our websites and services easy and meaningful. To better understand how they are used, read more about the UFS cookie policy. By continuing to use this site you are giving us your consent to do this.

Accept